Search International and National Patent Collections
Refine Search
Query Tree
Save query
A private query is only visible to you when you are logged-in and can not be used in RSS feeds
Results 1-10 of 3,213 for Criteria:CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N) Office(s):all Language:en Stemming: false
Filters
1 2 3 4 5 6 7 8 9 10 11 12
Page: / 322
Analysis
List Length
TitleCtrPubDate
Appl.NoApplicantInventorInt.Class
Means for treating inflammatory diseases, autoimmune diseases and cancer
EP12.11.2008
07009444FRAUNHOFER GES FORSCHUNGHORN FRIEDEMANN
C12N 15/113
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
113
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
This invention relates to a compound, wherein said compound is (a) a polynucleotide comprising or consisting of a base sequence of contiguous bases from the sequence of any one of SEQ ID NOs: 1 to 5, said base sequence being at least 15 bases in length; (b) a polynucleotide having at least 80% sequence identity to the polynucleotide of (a) over the entire length of said base sequence; (c) an analog or derivative of (a) or (b); or (d) a polynucleotide or analog or derivative thereof which is complementary to the full length of any one of (a) to (c); wherein said polynucleotide having at least 80% sequence identity, said analog, or said derivative is capable of interacting with a nucleic acid comprising a double-stranded part, said part comprising the sequence of any one of SEQ ID NOs: 1 to 5. The sequences of SEQ ID NOs: 1 to 5 define the Stat3-binding region of the gene encoding the micro RNA miR-21 and homologues thereof.

METHANOGEN SUBSTRATE FOR BIOGAS PRODUCTION
US25.05.2017
15313328ROQUETTE FRERESHerve WYART
C12P 5/02
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
P
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
5
Preparation of hydrocarbons
02
acyclic

The use of a product for internal dehydration of hydrogenated sugar as a methanogen substrate in a method for biogas production, a composition including a monoanhydrohexitol (M), a dianhydrohexitol (D), and anhydrohexitol polymers (P), and a methanisation method.


BIVALENT ANTISENSE OLIGONUCLEOTIDES
US28.03.2013
13636459Moeller ThorleifMoeller Thorleif
C12N 15/113
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
113
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

The present invention provides bivalent molecules comprising a first oligonucleotide linked to a second oligonucleotide. The first and the second oligonucleotide are preferably linked via a linking moiety. Preferably, both the first and/or the second oligonucleotide comprise an antisense sequence complementary to a cellular RNA such as mRNA or microRNA.


HYPOTENSIVE AGENT CONTAINING PENTITOL OR HEXITOL AS ACTIVE INGREDIENT
JP04.11.2005
2004125370THREE-B CO LTDYOSHINARI ATSUSHIRO
A61K 36/7
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36
Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
06
Fungi, e.g. yeasts
07
Basidiomycota, e.g. Cryptococcus
PROBLEM TO BE SOLVED: To obtain a new ACE inhibitor having extremely high safety, and a new hypotensive agent having extremely high safety.

SOLUTION: The ACE (angiotensin converting enzyme) inhibitor contains a pentitol or a hexitol as an active ingredient. The most preferable active ingredients are mannitol and xylitol. Also, the ACE inhibitor and the hypotensive agent each contains the extract of Pleurotus comucopiae as an active ingredient. The ACE inhibitor does not has toxicity, does not affect living bodies, even when taken in a large amount, and furthermore has other advantages.

COPYRIGHT: (C)2006,JPO&NCIPI


METHOD FOR PRODUCING AZIDE SUGAR BY MICROORGANISM REACTION AND ENZYME REACTION
JP28.01.2010
2008181469KISHOTO SEISAN GIJUTSU KENKYUSHO:KKIKUMORI TAKESHI
C12N 9/02
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9
Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
02
Oxidoreductases (1.), e.g. luciferase
PROBLEM TO BE SOLVED: To provide a bacterium that belongs to the genus Klebsiella and has ability of producing L-tagatose from galactitol.

SOLUTION: The bacterium of the genus Klebsiella has ability of using 6-azide hexitol as a raw material in which the 6-position of hexose is azidated, oxidizing the 2-position and forming 6-azide ketohexose. Moreover, the bacterium of the genus Klebsiella has ability of isomerizing 6-azide ketohexose and producing 6-azide aldohexose. The 6-azide polyol dehydrogenase is produced by the bacterium, acts on 6-azide polyol and oxidizes the 2-position to give ketose so as to form 6-azide ketohexose. The 6-azide aldose isomerase isomerizes 6-azide ketohexose to produce 6-azide aldohexose.

COPYRIGHT: (C)2010,JPO&INPIT


Method for producing gamma-carboxylated proteins
EP09.03.2011
10185166MEDLMMUNE LTDFENGE CHRISTEL
C12N 9/64
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9
Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14
Hydrolases (3.)
48
acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)
50
Proteinases
64
derived from animal tissue, e.g. rennin
The present invention relates to methods and tools for producing large quantities of gamma-carboxylated protein comprising: (i) culturing a cell adapted to express a protein which requires gamma-carboxylation and ³-glutamyl carboxylase in a ratio of at least 10:1, under conditions suitable for expression of both proteins, and (ii) isolating gamma-carboxylated protein

Compositions and methods for producing gamma-carboxylated proteins
US21.04.2011
12950713Fenge ChristelFenge Christel
C12N 5/07
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07
Animal cells or tissues

The present invention relates to methods and tools for producing large quantities of gamma-carboxylated protein comprising: (i) culturing a cell adapted to express a protein which requires gamma-carboxylation and γ-glutamyl carboxylase in a ratio of at least 10:1, under conditions suitable for expression of both proteins, and (ii) isolating gamma-carboxylated protein.


METHOD FOR PRODUCING GAMMA-CARBOXYLATED PROTEINS
KR01.12.2006
1020067009338ASTRAZENECA ABFENGE CHRISTEL
C12N 15/63
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

The present invention relates to methods and tools for producing large quantities of gamma-carboxylated protein comprising: (i) culturing a cell adapted to express a protein which requires gamma-carboxylation and γ-glutamyl carboxylase in a ratio of at least 10:1, under conditions suitable for expression of both proteins, and (ii) isolating gamma-carboxylated protein.

© KIPO & WIPO 2007


METHOD FOR PRODUCING GAMMA-CARBOXYLATED PROTEINS
EP12.07.2006
04775534ASTRAZENECA ABFENGE CHRISTEL
C12N 9/64
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9
Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14
Hydrolases (3.)
48
acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)
50
Proteinases
64
derived from animal tissue, e.g. rennin
The present invention relates to methods and tools for producing large quantities of gamma-carboxylated protein comprising: (i) culturing a cell adapted to express a protein which requires gamma-carboxylation and ϝ-glutamyl carboxylase in a ratio of at least 10:1, under conditions suitable for expression of both proteins, and (ii) isolating gamma-carboxylated protein.

TNF 수퍼패밀리 수용체에 대한 스플라이스 스위칭 올리고머 및 질환 치료에 있어서의 그의 용도
KR27.10.2017
1020177029877더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐사자니 피터 엘.
C12N 15/113
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
113
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
TNF 수용체 (TNFR1 및 TNFR2) 및 TNFR 수퍼패밀리에 속하는 다른 수용체를 암호화하는 pre-mRNA의 스플라이싱을 조절하는 화합물을 이용하여 이들 수용체의 발현을 제어하기 위한 방법 및 조성물이 개시된다. 특히 이러한 화합물들은 상기 수용체의 막횡단 도메인의 제거를 유발하고, TNF-α 활성 또는 관련 리간드의 활성을 감소시키는 길항제로 작용하는 수용체의 가용성 형태를 생산한다. TNF-α 활성을 감소시킴은 TNF-α 활성과 연계된 염증성 질환 또는 증상을 치료 및 개선하는 방법을 제공한다. 마찬가지로, 다른 리간드들과 연계된 질환들도 유사한 방식으로 치료될 수 있다. 특히, 본 발명의 화합물은 스플라이스-스플라이스 스위칭 올리고머 (SSO)로서, 생체내에서 안정한 작은 분자이며, 서열 특이적 방식으로 RNA에 혼성화되고, 그의 표적과 결합하여 알엔아제 H에 의해 분해되지 않는다.

Results 1-10 of 3,213 for Criteria:CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N) Office(s):all Language:en Stemming: false
Filters
1 2 3 4 5 6 7 8 9 10 11 12
Page: / 322